GlassScriptPhysician profile
Eduardo Gonzalez
NPI 1740241629
$3,774.66
in general payments reported to CMS, 2019-2025
36 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $277 · 2021: $205 · 2022: $385 · 2023: $988 · 2024: $998 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $617.30 | 2019-2025 | |
| Lilly USA, LLC | $585.23 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.98 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $273.84 | 2022-2025 | |
| Novo Nordisk INC | $201.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $176.53 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $159.54 | 2023-2024 | Freestyle Libre 3 |
| Allergan, INC. | $159.04 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.05 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Astellas Pharma US INC | $105.60 | 2022-2025 | Veozah |
| Glaxosmithkline, LLC. | $100.81 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $90.30 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $84.27 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $75.76 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Astrazeneca Pharmaceuticals LP | $64.16 | 2019-2023 | Farxiga |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $61.81 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $44.87 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $39.79 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $38.06 | 2020 | |
| Amgen INC. | $37.94 | 2020-2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $32.19 | 2019-2023 | Dificid |
| Echosens North America, INC. | $29.30 | 2025 | Fibroscan |
| Biohaven Pharmaceutical Holding Company LTD. | $27.86 | 2022 | |
| Seqirus USA INC | $21.28 | 2019 | |
| Zyla Life Sciences, INC. | $19.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.04 | 2022 | |
| Medtronic USA, INC. | $17.40 | 2019 | |
| Pfizer INC. | $17.25 | 2019 | |
| Dexcom, INC. | $17.09 | 2023 | Dexcom G6 Transmitter |
| Althera Pharmaceuticals LLC | $15.94 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.34 | 2025 | Caplyta |
| Radius Health, INC. | $14.95 | 2021 | |
| Lupin INC. | $13.82 | 2020 | |
| Amarin Pharma, INC. | $13.24 | 2019 | |
| Shire North American Group INC | $12.90 | 2019 | |
| Genentech USA, INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.